T Cell News and Research

Latest T Cell News and Research

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International Inc. today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

From Baxter International Inc. 15 Oct 2009

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

15 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions about its new laboratory in Las Vegas in an interview of Matthew Schissler, founder and CEO, by analyst Francis Gaskins.

15 Oct 2009

Human brains have amazing ability to be energy efficient, say researchers

Our brains, it turns out, are eco-friendly. A study published in Science and reviewed by F1000 Biology members Venkatesh Murthy and Jakob Sorensen reveals that our brains have the amazing ability to be energy efficient.

15 Oct 2009

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

New maintenance medium for human embryonic and pluripotent stem cells

STEMCELL Technologies Inc. (STEMCELL) is pleased to announce the release of TeSR™2, a defined, animal-protein free maintenance medium for human embryonic and induced pluripotent stem cells. This medium takes a step towards addressing the needs of researchers working towards the culture of their cells in a medium free of animal-derived proteins.

15 Oct 2009

Envoy Therapeutics raises $8 million through private placement

Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced the closing of its first financing, an $8 million private placement of the company’s Series A Preferred Stock. Led by 5AM Ventures, other investors participating in the financing included Takeda Research Investment and Roche Venture Fund.

15 Oct 2009

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years. These molecular sites appear to result in some level of immunity to the new virus in people who were exposed to the earlier influenza viruses.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Much remains to be done for autism spectrum disorders, say experts

Scientific understanding and medical treatments for autism spectrum disorders (ASDs) have advanced significantly over the past several years, but much remains to be done, say experts from the Center for Autism Research at The Children's Hospital of Philadelphia who published a scientific review of the field today.

15 Oct 2009

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.

15 Oct 2009

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Relying on an independent study by the Institute of Medicine (IOM), Secretary of Veterans Affairs Eric K. Shinseki decided to establish a service-connection for Vietnam Veterans with three specific illnesses based on the latest evidence of an association with the herbicides referred to as Agent Orange.

15 Oct 2009

Nano Gen Teknolojileri to distribute Fluidigm's BioMark and EP1 genetic analysis systems in Turkey

Fluidigm Corporation, the inventor of integrated fluidic circuits (IFCs), has appointed Nano Gen Teknolojileri Ltd. as its exclusive distributor for the BioMark™ and EP1™ Systems for genetic analysis in Turkey. The BioMark System provides significant advantages for digital and real-time PCR, genotyping, single-cell gene expression, cancer detection and absolute quantification.

15 Oct 2009

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

MUC1 protein defends against the stomach ulcer bacterium, according to study

A special protein in the lining of the stomach has been shown to be an important part of the body's defense against the stomach ulcer bacterium Helicobacter pylori in a new study from the Sahlgrenska Academy at the University of Gothenburg. The discovery may explain why the bacterium makes some people more ill than others.

14 Oct 2009

T Cell News and Research

Latest T Cell News and Research

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas

Human brains have amazing ability to be energy efficient, say researchers

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

New maintenance medium for human embryonic and pluripotent stem cells

Envoy Therapeutics raises $8 million through private placement

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Much remains to be done for autism spectrum disorders, say experts

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Nano Gen Teknolojileri to distribute Fluidigm's BioMark and EP1 genetic analysis systems in Turkey

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Research scientists develop bioengineered treatment for targeting pancreatic cancer

MUC1 protein defends against the stomach ulcer bacterium, according to study

Immunology eBook

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Newsletters you may be interested in